SuperworthVeracyte free cash flow VCYT
Cash from operations less capital spending, by quarter and over the last twelve months, from 2012.
- Last 12 months, to Jun 30, 2026
- $166M
- Latest quarter, Q2 FY26
- $43M
- +33% on a year earlier
- Fiscal year 2025
- $126.6M
- +98% on the year before
Veracyte's free cash flow was $166M over the twelve months to Jun 30, 2026, up 98% on a year earlier.
In its latest quarter, Q2 FY26, it was $43M, up 33% on the same quarter a year before.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2025 | $126.6M | +98% |
| FY2024 | $63.8M | +86% |
| FY2023 | $34.3M | n/a |
| FY2022 | −$1M | n/a |
| FY2021 | −$37M | n/a |
| FY2020 | −$12.5M | n/a |
| FY2019 | −$6M | n/a |
| FY2018 | −$15.4M | n/a |
| FY2017 | −$25.7M | n/a |
| FY2016 | −$32.2M | n/a |
| FY2015 | −$33.1M | n/a |
| FY2014 | −$29.7M | n/a |
| FY2013 | −$20.5M | n/a |
| FY2012 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $43M | +33% | $166M | |
| Q1 FY26 | $32.3M | +810% | $155.3M | |
| Q4 FY25 | $48.8M | +139% | $126.6M | |
| Q3 FY25 | $42M | +51% | $98.2M | |
| Q2 FY25 | $32.3M | +21% | $84M | |
| Q1 FY25 | $3.5M | n/a | $78.5M | |
| Q4 FY24 | $20.4M | +56% | $63.8M | |
| Q3 FY24 | $27.7M | +144% | $56.5M | |
| Q2 FY24 | $26.8M | +106% | $40.1M | |
| Q1 FY24 | −$11.1M | n/a | $26.3M | |
| Q4 FY23 | $13.1M | +66% | $34.3M | |
| Q3 FY23 | $11.4M | +114% | $29.1M |
Against its peers
Companies in Medical - Diagnostics & Research nearest Veracyte's size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| VCYTVeracyte | 4.3% |
| CDNACareDx | n/m |
| BLLNBillionToOne | 0.7% |
| LNTHLantheus | 6.0% |
| CAICaris Life Sciences | 1.4% |
| BIOBio-Rad Laboratories | 3.6% |
| RVTYRevvity | 3.2% |
| MEDPMedpace | 3.8% |
| LHLabcorp | 4.3% |
| DGXQuest Diagnostics | 5.1% |
| NRCNRC Health | 4.5% |
| Peer median | 3.8% |
Where Veracyte ranks
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Veracyte
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.